NEWS

We’ve been busy. Catch up on the latest news, updates and happenings at Synthekine.

Press Releases

ALL2024 - 20232022 - 2020

Synthekine Granted U.S. FDA Fast Track Designation for CD19 CAR-T and Orthogonal IL-2 Investigational Therapy, SYNCAR-001 + STK-009, for the Treatment of Lupus Without Lymphodepletion

/in , /by

September 4, 2024

Read more

Synthekine Announces U.S. FDA Clearance of IND Application for CD19 CAR-T and Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, for Treatment of Lupus Without Lymphodepletion

/in , /by

March 26, 2024

Read more

Synthekine Presents Preclinical Data at SITC 38th Annual Meeting Demonstrating its IL-12 Partial Agonist, STK-026, Significantly Expands Therapeutic Window

/in , /by

November 3, 2023

Read more

Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies

/in , /by

July 27, 2023

Read more

Synthekine Announces Multiple Poster Presentations Showcasing Its Three Distinct Cytokine Engineering Platforms at American Association for Cancer Research (AACR) 2022 Annual Meeting

/in , /by

April 7, 2022

Read more

Synthekine Announces $107.5 Million Oversubscribed Series B Financing to Support Lead Programs to Clinical Proof of Concept, Advance Preclinical Programs and Platform

/in , /by

June 10, 2021

Read more

Synthekine Presents Data at AACR Annual Meeting 2021 Demonstrating Selective IL-2 Partial Agonist, STK-012, Promotes Anti-Tumor Response without Related Toxicities

/in , /by

April 10, 2021

Read more

Synthekine Presents Data at American Society of Hematology Annual Meeting Showing Orthogonal IL-2 Ligand Drives Deeper and More Durable Response of CD-19 CAR-T

/in , /by

December 7, 2020

Read more

Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases

/in , /by

September 17, 2020

Read more

Synthekine Granted U.S. FDA Fast Track Designation for CD19 CAR-T and Orthogonal IL-2 Investigational Therapy, SYNCAR-001 + STK-009, for the Treatment of Lupus Without Lymphodepletion

/in , /by

September 4, 2024

Read more

Synthekine Announces U.S. FDA Clearance of IND Application for CD19 CAR-T and Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, for Treatment of Lupus Without Lymphodepletion

/in , /by

March 26, 2024

Read more

Synthekine Presents Preclinical Data at SITC 38th Annual Meeting Demonstrating its IL-12 Partial Agonist, STK-026, Significantly Expands Therapeutic Window

/in , /by

November 3, 2023

Read more

Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies

/in , /by

July 27, 2023

Read more

Synthekine Announces Multiple Poster Presentations Showcasing Its Three Distinct Cytokine Engineering Platforms at American Association for Cancer Research (AACR) 2022 Annual Meeting

/in , /by

April 7, 2022

Read more

Synthekine Announces $107.5 Million Oversubscribed Series B Financing to Support Lead Programs to Clinical Proof of Concept, Advance Preclinical Programs and Platform

/in , /by

June 10, 2021

Read more

Synthekine Presents Data at AACR Annual Meeting 2021 Demonstrating Selective IL-2 Partial Agonist, STK-012, Promotes Anti-Tumor Response without Related Toxicities

/in , /by

April 10, 2021

Read more

Synthekine Presents Data at American Society of Hematology Annual Meeting Showing Orthogonal IL-2 Ligand Drives Deeper and More Durable Response of CD-19 CAR-T

/in , /by

December 7, 2020

Read more

Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases

/in , /by

September 17, 2020

Read more

Copyright 2024 – Synthekine